medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 1

<< Back Next >>

Ann Hepatol 2017; 16 (1)

Effects of Interleukin-4 and Interleukin-12b Gene Polymorphisms on Hepatitis B Virus Vaccination

Youn RE, Young SE, Hyun YJ, Oh S, Young CJ, Park H, Hyun SS, Shin S

Language: English
References: 31
Page: 63-70
PDF size: 159.95 Kb.


ABSTRACT

Approximately 10% of individuals do not respond to hepatitis B virus (HBV) vaccination, i.e. non-responders (NRs). We aimed to investigate the association of interleukin (IL)-4 and IL-12B gene polymorphisms with responsiveness to the HBV vaccine in Korean infants. Among 300 healthy infants (9-12 month), SNPs for the IL-4 gene (rs2243250, rs2070874, and rs2227284) and for the IL-12B gene (rs3213094 and rs17860508) were compared between subgroups in terms of the response to HBV vaccination. The percentages of NRs (‹ 10 mIU/mL), low-titer responders (LRs, 10-100 mIU/mL), and high-titer responders (HRs, ≥ 100 mIU/mL) were 20.3%, 37.7% and 42.0%, respectively. No SNPs differed in frequency between NRs and responders or between LRs and HRs. We divided the subjects into two groups according to the time interval from the 3rd dose of HBV vaccination to Ab quantification: > 6 months from the 3rd dose (n = 87) and ≤ 6 months from the 3rd dose (n = 213). In the ≤ 6 month subjects, rs2243250C and rs2227284G were significantly frequent in the lower-titer individuals (NRs + LR) than HRs (40.1 vs. 25.9%, p = 0.014 and 45.1 vs. 33.0%, p = 0.018, respectively), and the rs2243250C and rs2227284G frequencies were significantly different among the three subgroups (13.2 vs. 26.9 vs. 25.9%, p = 0.040 and 15.5 vs. 29.6 vs. 33.0%, p = 0.038, respectively). In conclusion, those results suggest that IL-4 gene polymorphisms may play a role in the response to the HBV vaccine in Korean infants.


REFERENCES

  1. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. In Geneva, World Health Organization, 2015, p XIX. Available at: http://apps.who.int/iris/bitstream/10665/154590/ 1/9789241549059_eng.pdf

  2. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75 [PUBMED: 17393513].

  3. Koff RS. Review article: vaccination and viral hepatitis - current status and future prospects. Aliment Pharmacol Ther 2007; 26: 1285-92 [PUBMED: 17868433].

  4. Kim H, Shin AR, Chung HH, Kim MK, Lee JS, Shim JJ, Kim BH. Recent trends in hepatitis B virus infection in the general Korean population. The Korean Journal of Internal Medicine 2013; 28: 413-9 [PUBMED: 23864799].

  5. Papastergiou V, Lombardi R, MacDonald D, Tsochatzis EA. Global epidemiology of hepatitis B virus (HBV) infection. Curr Hepatology Rep 2015;14:171-8. Doi: 10.1007/s11901-015- 0269-3

  6. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol 2011; 17: 87-95 [PUBMED: 21757978].

  7. Cho YK, Song BC. Prevention of viral hepatitis and vaccination. Korean J Med 2012; 82: 123-33. Doi: http://dx.doi.org/ 10.3904/kjm.2012.82.2.123

  8. Jo DS, Kim JH, Choi EH, Park SE, Kim YJ, Kim YK, Lee J, et al. Recommended immunization schedule for children and adolescents: the Korean Pediatric Society, 2013. Korean J Pediatr 2013; 56: 231-4 [PUBMED: 23807888].

  9. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998; 15: 1-8 [PUBMED: 9651632].

  10. Choe BH. Hepatitis B vaccine: Prevention of perinatal infection and management of nonresponder. Korean J Pediatr Gastroenterol Nutr 2007; 10: 91-100. Available at: http:// dx.doi.org/10.3345/kjp.2007.50.9.823.

  11. Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992; 14: 27-30 [PUBMED: 1532609].

  12. Fleming SJ, Moran DM, Cooksley WG, Faoagali JL. Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Infect 1991; 22: 251-7 [PUBMED: 1830073].

  13. Yoon JH, Shin S, In JW, Chang JY, Song EY, Roh EY. Association of HLA alleles with the responsiveness to hepatitis B virus vaccination in Korean infants. Vaccine 2014; 32: 5638- 44 [PUBMED: 25148772].

  14. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9: 480-90 [PUBMED: 19543225].

  15. Ovsyannikova IG, Jacobson RM, Dhiman N, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics 2008; 121: e1091-e1099 [PUBMED: 18450852].

  16. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008; 26: D35-40 [PUBMED: 19230157].

  17. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009; 10: 837-52 [PUBMED: 19450131].

  18. Chen J, Liang Z, Lu F, Fang X, Liu S, Zeng Y, Zhu F, et al. Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine 2011; 29: 706-11 [PUBMED: 21111021].

  19. Pan L, Zhang W, Liang Z, Wu X, Zhu X, Li J, Li T, et al. Association between polymorphisms of the cytokine and cytokine receptor genes and immune response to hepatitis B vaccination in a Chinese Han population. J Med Virol 2012; 84: 26-33 [PUBMED: 22052597].

  20. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994; 15: 406-11 [PUBMED: 7524518].

  21. Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 2000; 105: 1063-70 [PUBMED: 10856136].

  22. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens 1994; 43: 18-27 [PUBMED: 8023317].

  23. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995; 310: 170 [PUBMED: 7833759].

  24. Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology 2006; 117: 289-300 [PUBMED: 16476048].

  25. Lee S, Chung W, Hyun KR. Socioeconomic costs of liver disease in Korea. Korean J Hepatol 2011; 17: 274-91 [PUBMED: 22310792].

  26. Jafarzadeh A, Shokri F. TH1 and TH2 responses are influenced by HLA antigens in healthy neonates vaccinated with recombinant hepatitis B vaccine. Iran J Allergy Asthma Immunol 2012; 11: 308-15 [PUBMED: 23264407].

  27. Wang Y, Xu P, Zhu D, Zhang S, Bi Y, Hu Y, Zhou YH. Association of polymorphisms of cytokine and TLR-2 genes with long-term immunity to hepatitis B in children vaccinated early in life. Vaccine 2012; 30: 5708-13 [PUBMED: 22824342].

  28. Cui W, Sun CM, Deng BC, Liu P. Association of polymorphisms in the interleukin-4 gene with response to hepatitis B vaccine and susceptibility to hepatitis B virus infection: a meta-analysis. Gene 2013; 525: 35-40 [PUBMED: 23651591].

  29. Grzegorzewska AE, Wobszal PM, Sowinska A, Mostowska A, Jagodzinski PP. Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection. Mol Biol Rep 2013; 40: 6899-911 [PUBMED: 24158609].

  30. Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol 2006; 3: 97-106 [PUBMED: 16696896].

  31. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493-503 [PUBMED: 12601343].




2020     |     www.medigraphic.com